Vaccination with DC-SIGN-Targeting αGC Liposomes Leads to Tumor Control, Irrespective of Suboptimally Activated T-Cells
Authors:
- Aram M. de HaasAHAram M. de Haas
- Dorian A. StolkDSDorian A. Stolk
- Sjoerd T. T. SchettersSSSjoerd T. T. Schetters
- Laura Goossens-KruijssenLGLaura Goossens-Kruijssen
- Eelco KeuningEKEelco Keuning
- Martino AmbrosiniMAMartino Ambrosini
- Louis BoonLBLouis Boon
- Hakan KalayHKHakan Kalay
- Gert StormGSGert Storm
- Hans J. van der VlietHVHans J. van der Vliet
- Tanja D. de GruijlTanja D. de Gruijl
- Yvette van KooykYKYvette van Kooyk
Open Access
- 24 April 2024
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (5) , 581
Abstract
Cancer vaccines have emerged as a potent strategy to improve cancer immunity, with or without the combination of checkpoint blockade. In our investigation, liposomal formulations containing synthetic long peptides and α-Galactosylceramide, along with a DC-SIGN-targeting ligand, Lewis Y (LeY), were studied for their anti-tumor potential. The formulated liposomes boosted with anti-CD40 adjuvant demonstrated robust invariant natural killer (iNKT), CD4+, and CD8+ T-cell activation in vivo. The incorporation of LeY facilitated the targeting of antigen-presenting cells expressing DC-SIGN in vitro and in vivo. Surprisingly, mice vaccinated with LeY-modified liposomes exhibited comparable tumor reduction and survival rates to those treated with untargeted counterparts despite a decrease in antigen-specific CD8+ T-cell responses. These results suggest that impaired induction of antigen-specific CD8+ T-cells via DC-SIGN targeting does not compromise anti-tumor potential, hinting at alternative immune activation routes beyond CD8+ T-cell activation.Keywords
Funding Information
- KWF Kankerbestrijding (KWFVU2014-7200, LSHM18056-SGF, 339977-Glycotreat, SPI-93-538)
- LSH-TKI project DC4Balance (KWFVU2014-7200, LSHM18056-SGF, 339977-Glycotreat, SPI-93-538)
- European Research Council (KWFVU2014-7200, LSHM18056-SGF, 339977-Glycotreat, SPI-93-538)
- ASPINOZA-NWO (KWFVU2014-7200, LSHM18056-SGF, 339977-Glycotreat, SPI-93-538)
This publication has 27 references indexed in Scilit:
- Liposome induction of CD8+ T cell responses depends on CD169+ macrophages and Batf3-dependent dendritic cells and is enhanced by GM3 inclusionJournal of Controlled Release, 2021
- Adaptable antigen matrix platforms for peptide vaccination strategies and T cell-mediated anti-tumor immunityBiomaterials, 2020
- Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitorsInternational Immunopharmacology, 2018
- KLRG1+ Effector CD8+ T Cells Lose KLRG1, Differentiate into All Memory T Cell Lineages, and Convey Enhanced Protective ImmunityImmunity, 2018
- Orchestrating immune responses: How size, shape and rigidity affect the immunogenicity of particulate vaccinesJournal of Controlled Release, 2016
- The nanoparticulation by octaarginine-modified liposome improves α-galactosylceramide-mediated antitumor therapy via systemic administrationJournal of Controlled Release, 2013
- Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentationMolecular Immunology, 2013
- DC-SIGN mediated antigen-targeting using glycan-modified liposomes: Formulation considerationsInternational Journal of Pharmaceutics, 2011
- Inflammation Directs Memory Precursor and Short-Lived Effector CD8+ T Cell Fates via the Graded Expression of T-bet Transcription FactorImmunity, 2007
- Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spotsLipids, 1970